Pklr Antibody

What is PKLR and why is it significant in research applications?

PKLR (Pyruvate kinase isozymes R/L) is a glycolytic enzyme that catalyzes the transphosphorylation from phosphoenolpyruvate (PEP) to ADP, yielding pyruvate and ATP. This represents the final step of the glycolytic pathway and is essentially irreversible. PKLR is also known by several alternative names including PK1, PKL, and Red cell/liver pyruvate kinase . The significance of PKLR in research stems from its critical role in cellular metabolism and its association with specific pathologies. Defects in this enzyme, resulting from gene mutations or genetic variations, are a common cause of chronic hereditary nonspherocytic hemolytic anemia (CNSHA or HNSHA) . Recent studies have also implicated PKLR in non-alcoholic fatty liver disease (NAFLD), making it an important target for researchers investigating metabolic disorders .

What are the optimal applications for PKLR antibodies in experimental protocols?

PKLR antibodies have demonstrated efficacy across multiple experimental applications, with the most validated being Western Blot (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), and ELISA . Based on published validation data, these antibodies show reliable reactivity with human, mouse, and rat samples . For Western Blot applications, PKLR antibodies have been successfully used with various cell lines including K-562, HT-29, and HeLa, as well as tissue samples from mouse kidney, mouse liver, and human HepG2 cells . For immunohistochemistry, PKLR antibodies have been validated on human liver tissue, human kidney tissue, and human intestinal cancer tissue . When designing experiments, researchers should consider that PKLR protein typically appears at the observed molecular weight of 58-62 kDa on Western blots, which aligns with its calculated molecular weight of 62-63 kDa (574-585 amino acids) .

What dilution parameters are recommended for different experimental techniques?

The optimal dilution parameters vary significantly depending on the specific application and antibody source. For Western Blot applications, the recommended dilutions range from 1:500-1:2400 for polyclonal antibodies like 17580-1-AP , while monoclonal antibodies such as ab171744 perform optimally at 1:1000 dilution . For Immunohistochemistry applications, the recommended dilution range is typically 1:50-1:500 for polyclonal antibodies , with specific monoclonal antibodies like ab171744 showing optimal results at 1:250 dilution . For Immunoprecipitation protocols, a typical recommendation is to use 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate . These values should be considered starting points, as the manufacturer guidelines consistently recommend that researchers titrate the reagent in each testing system to obtain optimal results, as performance can be sample-dependent .

What antigen retrieval methods are most effective for PKLR immunohistochemistry?

For optimal immunohistochemical detection of PKLR, antigen retrieval methods play a crucial role in ensuring specific and robust staining. The literature suggests two primary effective approaches: (1) Using TE buffer at pH 9.0, which is the primary suggested method for antibodies such as 17580-1-AP , and (2) Using citrate buffer at pH 6.0, which is recommended as an alternative method by multiple manufacturers and has been validated with antibodies like ab171744 . When performing heat-mediated antigen retrieval with citrate buffer pH 6.0, this should be completed before commencing with the IHC staining protocol . Choosing between these methods may depend on the specific tissue being examined and the particular antibody being used. Some tissues may show improved staining with one method over the other, necessitating optimization for each experimental condition. Researchers should follow manufacturer recommendations as a starting point, but validation within their specific experimental system remains essential.

Which positive controls are recommended for validating PKLR antibody specificity?

When validating PKLR antibodies, selecting appropriate positive controls is essential for confirming antibody specificity and functionality. For Western Blot applications, validated positive controls include K-562 cells, mouse kidney tissue, mouse liver tissue, NIH/3T3 cells, human HepG2 whole cell lysate, rat liver tissue, HT-29 cell lysate, and HeLa cell lysate . For Immunoprecipitation protocols, K-562 cells have been validated as a reliable positive control . For Immunohistochemistry applications, human liver tissue serves as the primary recommended positive control, with human intestinal cancer tissue and human kidney tissue also showing validated PKLR expression . The observed molecular weight of PKLR in Western blots typically ranges from 58-62 kDa, providing an additional parameter for verification . Researchers should select controls based on their experimental system and the specific antibody being used, as reactivity profiles may vary between different antibody products despite targeting the same protein.

How can researchers effectively troubleshoot inconsistent PKLR antibody performance?

Troubleshooting inconsistent PKLR antibody performance requires a systematic approach addressing multiple potential variables. First, evaluate antibody storage conditions—PKLR antibodies should be stored at -20°C and are typically stable for one year after shipment when properly handled . For long-term storage, consider that aliquoting may be unnecessary for -20°C storage according to manufacturer recommendations . Second, examine buffer compatibility—most PKLR antibodies are formulated in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which could interact with certain experimental buffers . Third, assess epitope accessibility issues, particularly in IHC applications, by comparing antigen retrieval methods (TE buffer pH 9.0 versus citrate buffer pH 6.0) . Fourth, verify target specificity through a multi-validation approach—consider using different antibodies targeting distinct epitopes of PKLR to confirm specificity, such as comparing results between polyclonal (17580-1-AP) and monoclonal (ab171744) antibodies . Fifth, for Western blot applications specifically, inconsistent results may stem from sample preparation issues—ensure complete protein denaturation and appropriate loading concentrations, noting that PKLR expression levels vary significantly between tissue types, with liver and erythroid cells showing higher expression.

What methodological considerations apply when studying PKLR in disease models?

When investigating PKLR in disease models, several methodological considerations must be addressed for rigorous experimental design. First, tissue selection is critical—PKLR shows tissue-specific expression patterns, predominantly in liver and erythroid cells, requiring careful selection of appropriate disease models . Second, consider isoform specificity—PKLR gene encodes both the liver (L) and erythrocyte (R) isozymes through alternative splicing, necessitating antibodies that can distinguish between these isoforms or capture both when relevant . Third, when studying hereditary nonspherocytic hemolytic anemia (HNSHA), design experiments that can detect functional alterations in PKLR beyond simple expression differences, as mutations may affect enzyme activity without changing protein levels . Fourth, for non-alcoholic fatty liver disease (NAFLD) studies, recent research has implicated PKLR involvement, suggesting experimental designs should incorporate metabolic pathway analyses alongside PKLR expression studies . Fifth, consider genetic background effects—PKLR mutations have variable penetrance and expressivity depending on genetic background, requiring well-characterized control populations in human studies . Finally, develop quantitative methodologies for assessing PKLR activity in addition to expression levels, as functional deficiencies may be more relevant than absolute protein amounts in disease states.

What are the critical factors in comparing polyclonal versus monoclonal PKLR antibodies?

When selecting between polyclonal and monoclonal PKLR antibodies, researchers must consider several critical factors that impact experimental outcomes. First, epitope recognition patterns differ significantly—polyclonal antibodies like 17580-1-AP recognize multiple epitopes on the PKLR protein, potentially offering greater sensitivity but increased risk of cross-reactivity, while monoclonal antibodies like ab171744 [EPR11093] target a single epitope, providing higher specificity but potentially lower sensitivity . Second, application compatibility varies—while both types have been validated for WB and IHC applications, their optimal working dilutions differ substantially (polyclonals typically 1:500-1:2400 for WB; monoclonals 1:1000) . Third, lot-to-lot consistency should be considered—monoclonal antibodies typically offer superior reproducibility between lots compared to polyclonals, which may show batch variations . Fourth, specific mutation detection capabilities differ—polyclonal antibodies may detect PKLR protein even when mutations are present in some epitopes, while monoclonal antibodies might fail to recognize the protein if their specific epitope is altered . Fifth, consider validation status—recombinant monoclonal antibodies like ab171744 often undergo more rigorous validation procedures, including specificity testing against multiple cell lines and tissues . Finally, research goal alignment is essential—exploratory studies might benefit from polyclonal antibodies' broader epitope recognition, while targeted analyses of specific PKLR forms or quantitative comparisons might be better served by monoclonal antibodies' consistency.

What experimental approaches can assess PKLR post-translational modifications?

Investigating PKLR post-translational modifications (PTMs) requires specialized experimental approaches beyond standard antibody applications. First, phosphorylation-specific techniques are crucial—since PKLR activity is regulated by phosphorylation, researchers should consider using phospho-specific antibodies in combination with general PKLR antibodies, along with phosphatase treatments as controls to confirm specificity of phosphorylation detection . Second, mass spectrometry approaches provide comprehensive PTM mapping—immunoprecipitate PKLR using validated antibodies like 17580-1-AP (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) followed by mass spectrometry analysis to identify specific modification sites . Third, molecular weight shift analyses on Western blots can indicate the presence of PTMs—compare observed molecular weights (typically 58-62 kDa for PKLR) with predicted weights to detect potential modifications . Fourth, enzymatic treatments prior to immunoblotting can reveal specific modifications—treat samples with glycosidases, phosphatases, or other PTM-removing enzymes before Western blotting to identify the nature of modifications. Fifth, assess functional consequences of PTMs by combining activity assays with PTM detection—correlate PKLR enzymatic activity with specific modification states to understand functional relevance. Finally, consider cell-specific and disease-relevant modifications—PKLR may undergo different modifications in liver versus erythroid cells, or in disease states such as HNSHA or NAFLD, requiring context-specific experimental designs .

How can researchers optimize Western blot protocols for PKLR detection?

Optimizing Western blot protocols for PKLR detection requires attention to several key technical parameters. First, sample preparation significantly impacts results—PKLR is optimally extracted in RIPA buffer supplemented with protease inhibitors, with samples prepared from tissues showing high PKLR expression such as liver or from validated cell lines including K-562, HT-29, HeLa, or NIH/3T3 . Second, protein loading amounts should be carefully calibrated—for cell lines with high PKLR expression, 10-20 μg of total protein is typically sufficient, while tissues may require optimization based on PKLR abundance . Third, gel percentage selection affects resolution—10-12% polyacrylamide gels provide optimal separation for PKLR, which has an observed molecular weight of 58-62 kDa . Fourth, transfer conditions impact detection sensitivity—semi-dry transfers at 15-20V for 30-45 minutes or wet transfers at 100V for 60-90 minutes at 4°C yield optimal results for PKLR . Fifth, blocking conditions should be optimized—5% non-fat dry milk in TBST provides effective blocking while maintaining antibody accessibility to PKLR epitopes . Sixth, primary antibody incubation parameters vary by antibody type—polyclonal antibodies like 17580-1-AP perform optimally at dilutions of 1:500-1:2400, while monoclonal antibodies like ab171744 show best results at 1:1000 dilution, with overnight incubation at 4°C recommended for both . Finally, detection methods should be matched to expression levels—standard ECL is sufficient for high-expression samples, while enhanced chemiluminescence or fluorescent secondary antibodies may improve detection in low-expression contexts.

What approaches enable quantitative analysis of PKLR expression levels?

Quantitative analysis of PKLR expression requires rigorous methodological approaches to ensure reliable and reproducible results. First, Western blot quantification should include proper normalization—use housekeeping proteins appropriate for the specific tissue or cell type being studied, and validate that treatments do not affect the reference protein expression . Second, establish a standard curve using recombinant PKLR protein at known concentrations to enable absolute quantification rather than merely relative comparisons . Third, employ quantitative PCR to complement protein-level data—design primers specific to PKLR isoforms (liver and erythroid) to distinguish between expression patterns of alternative transcript variants . Fourth, consider ELISA-based quantification—PKLR antibodies have been validated for ELISA applications, enabling more precise quantification than semi-quantitative Western blotting . Fifth, include appropriate biological replicates and technical repeats—PKLR expression can vary significantly between individuals and sample preparations, requiring sufficient replication to establish statistically significant differences . Sixth, utilize image analysis software with validated algorithms for densitometric analysis of Western blots—software should include background subtraction capabilities and options for different quantification methods (area under curve, peak height, etc.) . Finally, when comparing PKLR expression across different experimental conditions, process all samples simultaneously using identical protocols to minimize technical variability that could confound biological differences.

How can PKLR antibodies contribute to metabolic pathway analysis studies?

PKLR antibodies offer valuable tools for investigating metabolic pathways, particularly glycolysis and its regulation in various physiological and pathological contexts. First, multi-protein co-expression analysis can reveal regulatory relationships—combine PKLR antibodies with antibodies against other glycolytic enzymes and regulatory proteins to map pathway coordination in different tissues or disease states . Second, metabolic flux analysis can be enhanced—pair PKLR protein quantification using antibody-based methods with metabolite measurements to correlate enzyme abundance with pathway activity . Third, cell-type specific metabolism can be investigated—use PKLR antibodies in immunohistochemistry to identify cell populations with high glycolytic activity within heterogeneous tissues, particularly in liver where zonation affects metabolic function . Fourth, regulatory mechanism studies benefit from specific detection—investigate how PKLR responds to nutritional status, hormonal signals, or disease conditions by quantifying protein levels alongside post-translational modifications . Fifth, researchers can develop high-throughput screening approaches—use PKLR antibodies in plate-based assays to identify compounds that modulate enzyme expression as potential therapeutic candidates for metabolic disorders . Finally, differential isoform expression analysis provides tissue-specific insights—selective antibodies can distinguish between liver (L) and erythrocyte (R) isoforms, enabling studies of tissue-specific metabolic regulation that could inform targeted therapeutic approaches .

What considerations apply when using PKLR antibodies in single-cell analysis techniques?

Applying PKLR antibodies in single-cell analysis techniques requires specific methodological considerations to generate reliable data at the individual cell level. First, antibody specificity becomes even more critical—at the single-cell level, cross-reactivity can severely confound results, making validated monoclonal antibodies like ab171744 potentially advantageous despite their higher cost . Second, signal amplification strategies may be necessary—standard immunofluorescence may not provide sufficient sensitivity for detecting PKLR in all expressing cells, requiring tyramide signal amplification or similar techniques to enhance detection . Third, multiplexing capabilities should be evaluated—when combining PKLR detection with other markers in single-cell analyses, select antibodies raised in different host species or use sequential staining protocols to minimize cross-reactivity . Fourth, for flow cytometry applications, cell fixation and permeabilization protocols require optimization—PKLR is intracellular, requiring effective permeabilization while maintaining cellular integrity and epitope accessibility . Fifth, for imaging-based single-cell analysis, background autofluorescence must be carefully managed—particularly in tissues with high metabolic activity like liver, employ appropriate autofluorescence quenching methods and spectral unmixing . Finally, quantitative analysis of single-cell data requires appropriate controls—include both positive control cells with known PKLR expression (e.g., hepatocytes, erythroid precursors) and negative control populations to establish detection thresholds and account for technical variables .

How do researchers validate novel PKLR antibodies for research applications?

Validating novel PKLR antibodies requires a comprehensive approach encompassing multiple complementary techniques. First, Western blot validation should confirm specificity—test the antibody against samples known to express PKLR (K-562 cells, liver tissue) and negative controls, verifying the expected molecular weight of 58-62 kDa . Second, knockdown or knockout validation provides definitive specificity confirmation—compare antibody staining in wild-type cells versus those with PKLR knockdown by siRNA or CRISPR-Cas9, expecting significant signal reduction in the latter . Third, peptide competition assays assess epitope specificity—pre-incubate the antibody with excess immunizing peptide before application to samples, which should abolish specific staining if the antibody is truly targeting PKLR . Fourth, cross-reactivity assessment across species is essential—test the antibody against samples from different species (human, mouse, rat) to determine the range of experimental models in which it can be applied . Fifth, application-specific validation ensures utility across techniques—systematically test the antibody in all intended applications (WB, IHC, IP, ELISA) with appropriate positive controls for each method . Finally, comparative validation against established antibodies builds confidence—test the novel antibody alongside well-characterized PKLR antibodies like 17580-1-AP or ab171744, comparing staining patterns and signal intensities across multiple samples and techniques . This comprehensive validation approach ensures that novel antibodies will provide reliable results in diverse research applications.

What emerging technologies may enhance PKLR antibody applications in research?

The landscape of PKLR antibody applications is rapidly evolving with several emerging technologies poised to expand their research utility. First, proximity ligation assays (PLA) offer enhanced sensitivity and specificity—combining PKLR antibodies with antibodies against interaction partners in PLA formats could reveal previously undetectable protein-protein interactions relevant to metabolic regulation . Second, antibody-based imaging mass cytometry may revolutionize multiplex analysis—metal-tagged PKLR antibodies could enable simultaneous detection of dozens of proteins in single cells, providing unprecedented insights into metabolic heterogeneity within tissues . Third, automated high-content imaging platforms promise increased throughput—standardized PKLR antibody protocols optimized for automated imaging systems could facilitate large-scale screening of genetic or pharmacological perturbations affecting glycolytic regulation . Fourth, recombinant antibody engineering creates new possibilities—developing site-specific recombinant PKLR antibodies with enhanced specificity for particular post-translational modifications or isoforms could provide more precise tools for dissecting enzyme regulation . Fifth, microfluidic antibody-based assays may improve sensitivity and reduce sample requirements—miniaturized platforms using PKLR antibodies could enable analysis from limited clinical samples such as fine-needle biopsies or rare cell populations . Finally, combining antibody detection with single-cell transcriptomics offers integrated insights—correlating PKLR protein levels with gene expression profiles at single-cell resolution could reveal regulatory mechanisms governing glycolytic enzyme expression in health and disease .